Clinical Applications of Renin–Angiotensin System Inhibitors
£155
Clinical Applications of Renin–Angiotensin System Inhibitors
Edited by Michel Burnier
Description
Published February 2012
ISBN: 978-1-78084-078-9
Several newly identified components of the renin–angiotensin system have provided new insights into the role of the system in cardiovascular and renal physiology. The recent discovery of the renin and pro-renin receptor, the characterisation of the ACE-2 enzyme and the identification of several angiotensin II receptors have opened new research avenues in the field. This book provides an overview of related therapeutic approaches such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, direct renin inhibition and explores therapies involving RAS blockers alone and in combination approaches. Separate chapters address the renin–angiotensin system in the context of the heart, kidney and brain. The last chapter of this book addresses new therapeutic strategies involving the renin–angiotensin system, such as agonists of the angiotensin II AT2 receptor or agonists of the ACE-2 enzyme. This book addresses current approaches and gives useful insight into the new approaches that are being uncovered as understanding of the system continues to improve.
Chapters
- Overview of the RAS
Cesar Cerezo & Luis M Ruilope - Angiotensin-converting enzyme inhibitors
Giorgio Gentile, Gianpaolo Reboldi, Fabio Angeli, Giovanni Mazzotta & Paolo Verdecchia - Angiotensin receptor blockers
Carmine Savoia & Massimo Volpe - Direct renin inhibition
Michel Azizi - Renin–angiotensin–aldosterone inhibitors in combination therapy
Fadi G Hage, Sulaf J Mansur & Suzanne Oparil - RAS and the heart
Paramjit S Tappia, Shelley Zieroth & Naranjan S Dhalla - RAS and the kidney
Niren K Shah, Katie Vogel-Anderson, Rushab Choksi & Benjamin J Epstein - Pathophysiologic role of brain RAS in stroke protection: role of RAS blockers
Steven G Chrysant - Current guidelines for drugs blocking the RAS
Bernard Waeber & François Feihl - Emerging drugs affecting the RAS
AH Jan Danser & Anton JM Roks
